Exploristics is now part of MMS

Bringing new depth to study design through integrated analytics and modeling

We look forward to delivering even greater value… through optimized strategies that reduce the overall time and cost burden in drug development.
Chris Schoonmaker
Chief Operating Officer at MMS

Exploristics, the Northern Ireland-based biostatistics and data science company, has officially joined MMS. This integration includes KerusCloud®, a leading trial simulation platform that strengthens our ability to support complex development programs.

Expanded Capabilities for Sponsors

With the addition of the Exploristics team, MMS has enhanced its European footprint and added greater depth in statistical innovation and clinical trial simulation. The KerusCloud platform allows sponsors to explore trial scenarios in advance and improve the likelihood of regulatory success while reducing unnecessary cost and delay.

Our combined expertise supports sponsors through early-phase planning, strategic design selection, and regulatory readiness across multiple regions.

Exploristics visitors are invited to explore how our combined teams deliver on complex clinical development challenges.

A Stronger Future Together

With KerusCloud and MMS biometrics teams fully aligned, the same focus on modeling, simulation, and quality remains. Now, it is paired with deeper regulatory strategy and full-service biometrics. Sponsors working with the Exploristics team can expect the same support they know, with added global infrastructure and strategic consulting capabilities from MMS.

Together, we remain focused on building high-quality submissions, designing successful trials, and meeting the growing demands of clinical research with clarity and consistency.

Let us know how we can support your next project

Suggested For You

webinar

March 26th, 2026

Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 30th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today